Literature DB >> 3546170

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

C M Antunes, W Mayrink, P A Magalhaes, C A Costa, M N Melo, M Dias, M S Michalick, P Williams, A O Lima, J B Vieira.   

Abstract

Two controlled, double blind field trials of a non-living promastigote vaccine against New World Cutaneous Leishmaniasis (NWCL) were conducted in 1981 and 1983 in Brazil. Brazilian Army conscripts were randomly assigned to the vaccine or placebo groups and tested during their training in the Amazon jungle, a high risk area for NWCL. The results obtained showed: no significant differences between the vaccine and the placebo groups with respect to a number of characteristics (age, race, previous contact with the jungle, etc.); no significant differences between the participants who got and who did not get NWCL during the trial, with respect to length of exposure, contact with the jungle, etc. and a reduction of 67.3 and 85.7% in the annual incidence rate of NWCL, in 1981 and 1983 respectively (although the difference between incidence rates of the disease in vaccinated and control groups in the 1983 trial was not statistically significant), among those vaccinated who had converted to a positive leishmanin skin test as compared with the placebo groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3546170     DOI: 10.1093/ije/15.4.572

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  26 in total

1.  Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors.

Authors:  S Nylén; U Mörtberg; D Kovalenko; I Satti; K Engström; M Bakhiet; H Akuffo
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Dichotomy of protective cellular immune responses to human visceral leishmaniasis.

Authors:  E A G Khalil; N B Ayed; A M Musa; M E Ibrahim; M M Mukhtar; E E Zijlstra; I M Elhassan; P G Smith; P M Kieny; H W Ghalib; F Zicker; F Modabber; A M Elhassan
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

3.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

5.  Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8.

Authors:  M Colmenares; M Tiemeyer; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Authors:  Carmel B Stober; Selma M B Jeronimo; Nubia N Pontes; E Nancy Miller; Jenefer M Blackwell
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

7.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

8.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 9.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

10.  Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis.

Authors:  J E Haberer; A M Da-Cruz; L Soong; M P Oliveira-Neto; L Rivas; D McMahon-Pratt; S G Coutinho
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.